Rebbecca Wilson
Appearances
- DateMay 20, 2024The Phase 3 QUASAR Maintenance Study (NCT04033445) is a randomized-withdrawal, double-blind, placebo(PBO)-controlled, study that evaluated the efficacy and safety of maintenance treatment with subcutaneous (SC) guselkumab (GUS), an IL-23p19 subunit antagonist, in patients (pts) with moderately to s…
Presenter
University of Chicago Division of the Biological SciencesSpeakers
Brigham and Women's HospitalWestern UniversityUniversity of Pennsylvania
